[1]陈 立,刘亚庆,张利敏,等.干燥综合征患者血清人附睾蛋白4水平检测对肾损伤的预测价值研究[J].现代检验医学杂志,2025,40(03):183-188.[doi:10.3969/j.issn.1671-7414.2025.03.034]
　CHEN Li,LIU Yaqing,ZHANG Limin,et al.Study on the Predictive Value of Serum Human Epididymis Protein 4 Level Measurement in Patients with Sj?gren’s Syndrome for Renal Injury[J].Journal of Modern Laboratory Medicine,2025,40(03):183-188.[doi:10.3969/j.issn.1671-7414.2025.03.034]
点击复制

干燥综合征患者血清人附睾蛋白4水平检测对肾损伤的预测价值研究()

《现代检验医学杂志》[ISSN:/CN:]

卷:
第40卷
期数:
2025年03期
页码:
183-188
栏目:
论著
出版日期:
2025-05-15

文章信息/Info

Title:
Study on the Predictive Value of Serum Human Epididymis Protein 4 Level Measurement in Patients with Sj?gren’s Syndrome for Renal Injury
文章编号:
1671-7414（2025）03-183-06
作者:
陈 立，刘亚庆，张利敏，祝艺华，田慧群
（宜昌市第二人民医院/三峡大学第二人民医院检验科，湖北宜昌 443000）
Author(s):
CHEN Li，LIU Yaqing，ZHANG Limin，ZHU Yihua，TIAN Huiqun
（Department of Clinical Laboratory，the Second People’s Hospital of Yichang / the Second People’s Hospital of China Three Gorges University, Hubei Yichang 443000, China）
关键词:
原发性干燥综合征; 人附睾蛋白4; 肾损伤
分类号:
R593.2；R392.11
DOI:
10.3969/j.issn.1671-7414.2025.03.034
文献标志码:
A
摘要:
目的研究原发性干燥综合征（pSS）患者血清人附睾蛋白4（HE4）水平在肾脏损伤中的预测价值。方法回顾性分析2021年9月～2023年8月宜昌市第二人民医院收治的77例pSS患者作为研究组，其中肾损伤组43例，非肾损伤组34例；同期54例健康体检者（HCs）作为对照组。检测血清HE4，Cys-C，TNF-α，CR，C3，C4，免疫球蛋白、Anti-SSA和Anti-SSB等指标的表达水平，分析HE4在pSS患者肾损伤早期诊断中的价值。结果与HCs相比，pSS患者的HE4（120.02±103.86pmol/Lvs57.5±16.52pmol/L），Cys-C（1.30±0.81mg/Lvs0.87±0.14mg/L）水平升高，差异具有统计学意义（t=4.382，3.860，均P<0.05）。肾损害组血清HE4，Cys-C，CR及TNF-α水平均高于非肾损害组，差异具有统计学意义（t/χ2=2.552～4.371，均P<0.05）。Pearson相关分析显示，血清HE4，Cys-C，CR及TNF-α水平与pSS肾损害呈正相关（r=0.287～0.546，均P＜0.05）。Logistic回归分析显示，血清HE4水平升高可能是诱发pSS肾损害的独立危险因素（Waldχ2=11.932，P＜0.05）。受试者工作特征（ROC）曲线分析血清HE4诊断pSS肾损害的最佳临界值为70.46pmol/L，约登指数最大为0.625，AUC（95%CI）=0.876（0.799～0.954）。结论pSS患者血清HE4水平与肾损伤呈正相关，对是否发生肾脏损伤具有预测价值。
Abstract:
Objective To investigate the predictive value of serum human epididymis protein 4 (HE4) levels in primary Sj?gren’s syndrome (pSS) patients for renal injury. Methods A retrospective analysis of 77 pSS patients admitted to the Second People’s Hospital of Yichang from September 2021 to August 2023 was performed, including 43 cases of renal injury group 34 instances of non-renal injury group, and 54 healthy physical examination subjects (HCs) as control group. Fasting peripheral venous blood (4ml) was collected to detect the serum levels of HE4, Cys-C, TNF-α, CR, C3, C4, immunoglobulin, Anti-SSA, Anti-SSB and other indicators, and analyzed the value of HE4 in the early diagnosis of kidney injury in pSS patients. Results Compared with HCs, the pSS patients had increased levels of HE4 (120.02±103.86 pmol/L vs 57.5±16.52 pmol/L), Cys-C (1.30±0.81mg/L vs 0.87±014 mg/L), and the differences were statistically significant (t=4.382, 3.860，all P<0.05). The serum levels of HE4, CR and TNF-α in the renal damage group were higher than those in the non-renal damage group ，and the differences were statistically significant (t/χ2=2.552 ～ 4.371，all P<0.05). Pearson correlation analysis showed that, the levels of serum HE4, Cys-C, CR and TNF-α were all positively correlated with renal damage in pSS (r =0.287 ～ 0.546， all P < 0.05). Logistic regression analysis showed that elevated serum HE4 level might be an independent risk factor for inducing renal damage in pSS (Wald χ2=11.932, P < 0.05). Receiver operating characteristic (ROC) curve analysis showed that the best cut-off value of serum HE4 for the diagnosis of pSS renal damage was 70.46pmol/L, the maximum Youden index was 0.625, AUC(95%CI)=0.876 （0.799 ～ 0.954）.Conclusion The serum HE4 level in patients with pSS is positively correlated with renal injury and has predictive value for the occurrence of renal injury.

参考文献/References:

[1] BRITO-ZERON P, ACAR-DENIZLI N, NG W F, et al. Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sj?gren’s syndrome[J]. Rheumatology(Oxford, England), 2020, 59(9): 2350-2359.
[2] MARIETTE X, CRISWELL L A. Primary Sj?gren’s syndrome[J]. the New England Journal of Medicine, 2018, 378(10): 931-939.
[3] ZHAN Qipeng, ZHANG Jianan, LIN Yubin, et al. Pathogenesis and treatment of Sjogren’s syndrome:review and update[J]. Frontiers in Immunology, 2023, 14: 1127417.
[4] 邹瑶,凌光辉,田静,等.原发性干燥综合征肾损害研究进展[J]. 中南大学学报（医学版）,2018,43(3):320-326． ZOU Yao, LING Guanghui, TIAN Jing, et al. Research progress in renal injury relevant to primary Sj?gren’s syndrome[J]. Journal of Central South University:Medical Science, 2018, 43(3): 320-326.
[5] CHALKIA A, GIANNOU P, THOMAS K, et al. Distal renal tubular acidosis and nephrocalcinosis as initial manifestation of primary Sj?gren’s syndrome[J]. Saudi Journal of Kidney Diseases and Transplantation, 2021, 32(5): 1470-1474.
[6] LUO Jing, XU Shihao, LV Yinqiu, et al. Clinical features and potential relevant factors of renal involvement in primary Sj?gren’s syndrome[J]. International Journal of Rheumatic Diseases, 2019, 22(2): 182-190.
[7] LEES J S, WELSH C E, CELIS-MORALES C A, et al. Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease[J]. Nature Medicine, 2019, 25(11): 1753-1760.
[8] EBERT N, SHLIPAK M G. Cystatin C is ready for clinical use[J]. Current Opinion in Nephrology and Hypertension, 2020, 29(6): 591-598.
[9] 徐建波,高玲玲,王卫杰.CA125联合HE4在判断晚期卵巢癌新辅助化疗疗效的价值[J].分子诊断与治疗杂志,2023,15(12):2151-2154. XU Jianbo, GAO Lingling, WANG Weijie. Value of CA125 combined with HE4 in evaluating the efficacy of neoadjuvant chemothera-py for advanced ovarian cancer[J]. Journal of Molecular Diagnosis and Therapy, 2023, 15(12): 2151-2154.
[10] 刘检,李敏,陆明洋,等.卵巢癌患者血液NLR, CA125 ,HE4水平联合检测的实验诊断和预后价值研究[J].现代检验医学杂志,2021,36(5):28-32. LIU Jian, LI Min, LU Mingyang, et al. Experimental diagnosis and prognostic value of combined detection of blood NLR, CA125 and HE4 levels in ovarian cancer patients[J]. Journal of Modern Laboratory Medicine, 2021, 36(5): 28-32.
[11] DONG Cunyuan, FENG Shujuan, MA Haiqian, et al. Predictive value of serum human epididymis protein 4 for heart failure in patients with chronic kidney disease[J]. American Journal of Translational Research, 2023, 15(9): 5664-5673.
[12] CHHIKARA N, SARASWAT M, TOMAR A K, et al.Human epididymis protein-4 (HE-4): a novel cross-class protease inhibitor[J]. PLoS One, 2012, 7(11):e47672.
[13] 张文,厉小梅,徐东,等.原发性干燥综合征诊疗规范[J].中华内科杂志,2020,59(4):269-276. ZHANG Wen, LI Xiaomei, XU Dong, et al. Recommendations of diagnosis and treatment of primary Sj?gren’s syndrome in China[J]. Chinese Journal of Internal Medicine, 2020, 59(4): 269-276.
[14] GOULES A V, TATOULI I P, MOUTSOPOULOS H M, et al. Clinically significant renal involvement in primary Sj?gren’s syndrome: clinical presentation and outcome[J]. Arthritis and Rheumatism, 2013, 65(11):2945-2953.
[15] 张玉磊,高琼.血清胱抑素C、同型半胱氨酸及尿微量白蛋白联合检测诊断妊娠期高血压疾病患者早期肾功能损伤的价值[J].中国妇幼保健,2018,33(23):5422-5424. ZHANG Yulei, GAO Qiong. The value of combining serum cystatin C,homocysteine and urine microalbumin for the diagnosis of early renal impairment in patients with hypertensive diseases during pregnancy[J]. Maternal and Child Health Care of China, 2018, 33(23):5422-5424.
[16] BUNYA V Y, YING Guishuang, MAGUIRE M G, et al. Prevalence of novel candidate sjogren syndrome autoantibodies in the dry eye assessment and management (DREAM) study[J]. Cornea, 2018, 37(11):1425-1430.
[17] NEGRINI S, EMMI G, GRECO M, et al. Sj?gren’s syndrome: a systemic autoimmune disease[J]. Clinical and Experimental Medicine, 2022, 22(1): 9-25.
[18] LEBLEU V S, TENG Yingqi, O’CONNELL J T, et al. Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis[J]. Nature Medicine, 2013, 19(2): 227-231.
[19] NAGY B J, NAGY B, FILA L, et al. Human epididymis protein 4: a novel serum inflammatory biomarker in cystic fibrosis[J]. Chest, 2016, 150(3): 661-672.
[20] ZHANG Mingxia, ZHANG Liyun, E Linning, et al. Increased levels of HE4 (WFDC2) in systemic sclerosis: a novel biomarker reflecting interstitial lung disease severity? [J]. Therapeutic Advances in Chronic Disease, 2020, 11:2040622320956420.
[21] LI Liubing, XU Huiya, LE Yuting, et al. Elevated serum levels of human epididymis protein 4 in adult patients with proliferative lupus nephritis [J]. Frontiers in Immunology, 2023, 14: 1179986.
[22] 赵智凝,武易,刘芳,等.慢性肾病患者血清Klotho, HE4, UMOD表达水平与疾病预后的相关性研究[J].现代检验医学杂志,2021,36(2):28-31, 56. ZHAO Zhining, WU Yi, LIU Fang, et al. Study on the relationship between the expression level of klotho, HE4 and uromodulin and the development of chronic kidney disease[J].Journal of Modern Laboratory Medicine, 2021, 36(2): 28-31, 56.
[23] WANG Lunshan, SUN Yuhuai, CAI Xinan, et al. The diagnostic value of human epididymis protein 4 as a novel biomarker in patients with renal dysfunction[J]. International Urology and Nephrology, 2018, 50(11):2043-2048.
[24] 高冉冉,胡洪贞,韩聪,等.血清HE4在慢性肾脏病中的表达水平及机制研究进展[J].国际检验医学杂志,2023,44(1):100-104. GAO Ranran, HU Hongzhen, HAN Cong, et al. Research progress on the expression and mechanism of serum HE4 in chronic kidney disease[J]. International Journal of Laboratory Medicine, 2023, 44(1): 100-104.
[25] CHEN Peipei, YANG Qiao, LI Xuemei, et al. Potential association between elevated serum human epididymis protein 4 and renal fibrosis: a systemic review and meta-analysis[J]. Medicine, 2017, 96(36): e7824.
[26] YAMAMOTO M, HANATANI S, ARAKI S, et al. HE4 predicts progressive fibrosis and cardiovascular events in patients with dilated cardiomyopathy[J]. Journal of the American Heart Association, 2021, 10(15):e021069.
[27] ZHANG Lei, LIU Limin, BAI Ming, et al. Hypoxia-induced HE4 in tubular epithelial cells promotes extracellular matrix accumulation and renal fibrosis via NF-κB[J]. FASEB Journal, 2020, 34(2): 2554-2567.
[28] AIYEGBUSI O, MCGREGOR L, MCGEOCH L, et al. Renal disease in primary Sj?gren’s syndrome[J]. Rheumatology and Therapy, 2021, 8(1): 63-80.
[29] P?CSI M, FEJES Z, BENE Z, et al. Human epididymis protein 4 (HE4) plasma concentration inversely correlates with the improvement of cystic fibrosis lung disease in p.Phe508del-CFTR homozygous cases treated with the CFTR modulator lumacaftor/ivacaftor combination[J]. Journal of Cystic Fibrosis，2023, 22(6): 1085-1092.
[30] CHEN Jiali, SUN Feng, BAO Huizhang, et al. Elevated serum human epididymis protein 4 is associated with disease activity and systemic involvements in primary Sj?gren’s syndrome [J]. Frontiers in Immunology, 2021, 12: 670642.
[31] BENE Z, FEJES Z, SZANTO T G, et al. Enhanced expression of human epididymis protein 4 (HE4) reflecting pro-inflammatory status is regulated by CFTR in cystic fibrosis bronchial epithelial cells [J]. Frontiers in Pharmacology， 2021, 12: 592184.
[32] KUMRUNGSEE T, KARIYA T S, HASHIMOTO K, et al. The serum amyloid A3 promoter-driven luciferase reporter mice is a valuable tool to image early renal fibrosis development and shows the therapeutic effect of glucosyl-hesperidin treatment[J]. Scientific Reports, 2019, 9(1): 14101.
[33] 胡晓舟,崔丽艳,张捷.健康人群血清HE4水平参考区间的初步探讨[J].中华检验医学杂志,2009,32 (12):1376-1378. HU Xiaozhou, CUI Liyan, ZHANG Jie. Investigation on the reference range of human serum levels of human epididymis protein 4 in healthy people[J]. Chinese Journal of Laboratory Medicine, 2009, 32(12): 1376-1378.
?

相似文献/References:

[1]闫先侠,孙 晓,张 华,等.血清人附睾蛋白4联合CA125检测在卵巢癌诊断中的应用[J].现代检验医学杂志,2015,30(01):134.[doi:10.3969/j.issn.1671-7414.2015.01.040]
[2]赵智凝,武　易,刘　芳,等.慢性肾病患者血清Klotho，HE4，UMOD表达水平与疾病预后的相关性研究[J].现代检验医学杂志,2021,36(02):28.[doi:doi:10.3969/j.issn.1671-7414.2021.02.007]
　ZHAO Zhi-ning,WU Yi,LIU Fang,et al.Study on the Relationship between the Expression Level of Klotho, HE4 and Uromodulin and the Development of Chronic Kidney Disease[J].Journal of Modern Laboratory Medicine,2021,36(03):28.[doi:doi:10.3969/j.issn.1671-7414.2021.02.007]
[3]刘　检,李　敏,陆明洋,等.卵巢癌患者血液NLR，CA125，HE4水平联合检测的实验诊断和预后价值研究[J].现代检验医学杂志,2021,36(05):28.[doi:10.3969/j.issn.1671-7414.2021.05.006]
　LIU Jian,LI Min,LU Ming-yang,et al.Experimental Diagnosis and Prognostic Value of Combined Detection of BloodNLR, CA125 and HE4 Levels in Ovarian Cancer Patients[J].Journal of Modern Laboratory Medicine,2021,36(03):28.[doi:10.3969/j.issn.1671-7414.2021.05.006]

备注/Memo

备注/Memo:
基金项目：宜昌市医疗卫生科研项目（A22-22-051）。
作者简介：陈立（1988-），女，硕士研究生，主管技师，研究方向：临床血液及免疫学检验，E-mail：312284808@qq.com。
通讯作者：田慧群，硕士研究生，主要从事临床免疫学检验。
更新日期/Last Update: 2025-05-15